The hepatic–gut–brain (neural) axis plays a role in NAFLD progression via serotonin and the serotonin receptor HTR2A in hepatocytes, suggesting that HTR2A antagonists are potential therapeutic agents for NAFLD. This evidence concerns the gene HTR2A and metabolic dysfunction-associated steatotic liver disease.